title: Surgical treatment for hepatocellular carcinoma detected after successful interferon therapy.
abstract: OBJECTIVE
  Interferon therapy suppresses the development of hepatocellular carcinoma (HCC) and tumor recurrence after a resection of HCC in patients with chronic hepatitis C. However, the value of a liver resection and which method is best for the treatment of HCC detected after successful interferon therapy remains to be clarified. The risk factors for tumor recurrence after a liver resection for HCC detected after successful interferon therapy were investigated to determine the appropriate operative method for such HCC.
  
  
  METHODS
  Risk factors including the clinicopathologic findings and the operative methods for tumor recurrence were evaluated by univariate and multivariate analyses in 24 patients who underwent liver resection for HCC detected after successful interferon therapy (sustained viral response or biochemical response).
  
  
  RESULTS
  According to a univariate analysis, large tumor (> 2 cm, P = 0.0326), multiple tumors (P = 0.0372), nonanatomic resection (P = 0.0103), and positive surgical margin (< 5 mm of a free surgical margin, P = 0.0245) were possible risk factors for short tumor-free survival time after surgery. A multivariate analysis showed that large tumor (P = 0.0407), nonanatomic resection (P = 0.0215), and positive surgical margin (P = 0.0253) were independent risk factors for a short tumor-free survival time after surgery.
  
  
  CONCLUSIONS
  An anatomic resection with an appropriate surgical margin (> or = 5 mm of a free surgical margin) is recommended for patients with HCC detected after successful interferon therapy.
authors: Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
authors: Shoji
authors: S
authors: Kubo
authors: Hiromu
authors: H
authors: Tanaka
authors: Shigekazu
authors: S
authors: Takemura
authors: Satoshi
authors: S
authors: Yamamoto
authors: Seikan
authors: S
authors: Hai
authors: Tsuyoshi
authors: T
authors: Ichikawa
authors: Shintaro
authors: S
authors: Kodai
authors: Hiroji
authors: H
authors: Shinkawa
authors: Taichi
authors: T
authors: Shuto
authors: Kazuhiro
authors: K
authors: Hirohashi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000601:surgery; D016016:Proportional Hazards Models; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007372:Interferons